North American Star Consortium

北美明星财团

• 批准号: 10301455
• 负责人: Philippe Bedard
• 金额: $ 11.72万
• 依托单位: UNIVERSITY HEALTH NETWORK
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-07 至 2023-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10301455
• 关键词: Achievement; Address; Adherence; American; Cancer Center; Cancer Institute of New Jersey; Clinical Research; Clinical Trials; Collaborations; Development; Drug Kinetics; Enrollment; Faculty; Funding; Goals; Good Clinical Practice; Guidelines; Infrastructure; Institutes; Institution; Laboratories; Leadership; Malignant Neoplasms; Mentors; Mentorship; Monitor; Patients; Performance; Pharmacodynamics; Phase; Productivity; Publications; Recording of previous events; Reporting; Research Personnel; Science; Site; Texas; Tissue Banks; Toxic effect; Training; Translational Research; Tumor Tissue; Universities; Virginia; career; career development; design; early phase clinical trial; human subject protection; investigator-initiated trial; member; next generation; novel; programs; tissue biomarkers

Project Summary This subaward application of the Rutgers Cancer Institute of New Jersey, as an Affiliated Organization (AO) of the North American Star Consortium (NASC), with Salma Jabbour, MD, as the contact PI, will serve to continue the collaboration in early phase clinical trials with multiple renowned institutions. The Rutgers Cancer Institute of New Jersey has an established history of achievement within the ETCTN, with active leadership, dedicated infrastructure, and contributions toward the development and execution of ETCTN- sponsored early phase clinical trials as well as mentorship of Early Career Investigators. Our team will continue to collaborate within the existing infrastructure of the Princess Margaret Cancer Center, LAO of the NASC, which includes accomplished clinical trial programs and investigators from Moffitt Cancer Center, Virginia Commonwealth University-Massey Cancer Center, University of Texas Southwestern Simmons Cancer Center, and Northwestern Lurie Cancer Center. Rutgers Cancer Institute has demonstrated robust performance within the ETCTN for over a decade by leading impactful investigator-initiated trials generated by NCI-funded science and prioritizing the career development of junior faculty. The sustained productivity of the Rutgers Cancer Institute will continue to go forward within the NASC to address the following Specific Aims: 1. To participate and carry out novel phase 1 and phase 2 ETCTN trials through participation in the NASC. 2. To enroll patients on ETCTN trials that require the acquisition of high- quality tumor tissue for biomarker and pharmacodynamic analyses, include pharmacokinetic (PK) endpoints, and closely follow Good Clinical Practice and Human Subject Protection guidelines. 3. To mentor and develop the next generation of investigators in clinical and translational research.

项目摘要 这是新泽西州罗格斯癌症研究所作为附属组织的分奖申请 (Ao)北美明星联盟(NASC)的，以马里兰州萨尔玛·贾布尔为联系人PI，将担任 继续与多家知名机构在早期临床试验方面进行合作。罗格斯癌症 新泽西学院在ETCTN内部有着既定的成就历史，拥有积极的领导， 专用基础设施，以及对ETCTN赞助的早期项目的开发和执行作出的贡献 阶段性临床试验以及早期职业研究人员的指导。我们的团队将继续合作 在玛格丽特公主癌症中心的现有基础设施内，国家癌症中心的LAO包括 弗吉尼亚州联邦莫菲特癌症中心完成的临床试验计划和研究人员 大学-梅西癌症中心，德克萨斯大学西南西蒙斯癌症中心，以及 西北卢里癌症中心。罗格斯癌症研究所在 十多年来，ETCTN通过领导由NCI资助的科学产生的有影响力的研究人员发起的试验 优先考虑初级教师的职业发展。 罗格斯癌症研究所的持续生产力将在NASC内继续向前发展 解决以下具体目标：1.参与和开展新的第一阶段和第二阶段ETCTN试验 通过参与NASC。2.招募患者参加ETCTN试验，这些试验需要获得高- 用于生物标记物和药效学分析的优质肿瘤组织，包括药代动力学(PK)终点， 并严格遵守良好临床实践和人体主体保护指南。3.指导和发展 临床和转化性研究的下一代研究人员。